menu
Factsheet
November 05, 2019

Non-invasive Detection of Immunotherapy Biomarkers using TruSight Oncology 500 (TSO500)

TSO500 Plasma Assay
The TruSight Oncology 500 (TSO500) plasma assay employs a hybrid capture-based approach targeting 523 clinically relevant genes and leverages unique molecular indices to enable ultra-low frequency detection of SNVs, Indels, and CNVs. This comprehensive cancer panel interrogates relevant cancer biomarkers with as little as 20-30 ng of cfDNA and demonstrates robust analytical performance.

Download our factsheet to learn more.

Related Services:
Panel-based tumor mutational burden (TMB) analysis of matched tumor and plasma specimens using Illumina’s TruSight Oncology 500 next-generation sequencing assay

AACR 2019 Scientific Poster

Tumor Mutational Burden (TMB) Assay for Response to Immunotherapy

TMB assay utilizing whole exome sequencing (WES) methodology and proprietary variant analysis compendium

The standardization of Tumor Mutational Burden (TMB) by alignments to reference standards

Joined by Friends of Cancer Research (Friends)

Q2 Solutions Genomic Laboratory Services

Genomic Know-How® for your drug development needs

Read More